3647 results for «686»
3647 results
Rapid-fire - Challenging TAVI procedures - Part 4
20 Nov 2023 – From PCR London Valves 2023
Join this session for insights and innovative solutions to challenging TAVI procedures: explore the dynamics of peri-procedural ST-elevation myocardial infarction during TAVR, witness shifting left ventricular and hemodynamic physiology, unravel a curious case of valve-in-valve TAVR with a crossability challenge, confront the obstructive dilemma of high...
Navigating the crossroads of care: challenges in shared decision-making for doctors and patients
20 Nov 2023 – From PCR London Valves 2023
Tune in to understand the significance of shared decision-making, explore its importance, identify potential barriers, recognize the pivotal role of patient perspectives and engagement, and discover strategies to facilitate its successful integration on both local and global scales.
Top Innovations
20 Nov 2023 – From PCR London Valves 2023
Discover the future of cardiac care with these 3 top innovations! ARTERY, revolutionizing structural heart treatment, Vesalius Transfemoral DMR Repair, combining chordal and annular support in one-transfemoral device, and Approxima, a right ventricular reshaping device, offering a fresh perspective on tricuspid regurgitation.
Rapid-fire - Complex structural interventions
20 Nov 2023 – From PCR London Valves 2023
Explore groundbreaking cases in this session: choosing septal coiling over alcohol septal ablation in hypertrophic cardiomyopathy, managing a giant LAA with two Watchman Devices, treating a complex pseudoaneurysm in a patient with cardiogenic shock, and more!
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...
Author
